Industry News
List of FDA Approved PEGylated Drugs Up t…
History of PEGylated drugs, list of FDA approved PEGylated drugs, advantages and challenges of PEGylation.
Next-Generation ADC: How Bispecific ADCs …
On July 3, 2025, Biokin Pharma, a leading biopharma company based in China, announced that its proprietary bispecific ADC iza-bren (izalontamab brengitecan, BL-B01D1) met the primary endpoint…
AACR 2025 Highlights: Dual Payload & …
Discover key highlights from the 2025 AACR Annual Meeting, where cutting-edge ADC innovations—from dual-payloads to immunotherapy combos—are reshaping cancer treatment.
N-Benzylhydroxylamine Hydrochloride (CAS …
N-Benzylhydroxylamine hydrochloride (CAS 29601-98-7) is a versatile organic compound featuring a unique nitrogen–oxygen (N–O) functional group. This structural characteristic endows it with…
19 Approved ADCs Worldwide: The Ultimate …
As of 2025, a total of 19 ADC drugs have been approved globally.
The Next Generation of Obesity Treatments…
Recently, Nature published an in-depth report on the upcoming wave of next-generation weight-loss therapies.
Semaglutide & Tirzepatide: Leading GL…
Eli Lilly and Novo Nordisk are the undisputed leaders in the market for GLP-1 drugs, a class of medications used to treat both diabetes and obesity.
Promising MASH Therapies Under Develpment…
Currently, over 500 MASH therapies are in development worldwide, with 5 drugs having advanced to Phase 3 clinical trials.
FDA Approvals 2024 & Potential First-…
In this article, we will review the key highlights of FDA-approved therapies in 2024 and explore potential first-in-class therapies expected to gain approval in 2025.
Overview: ADC Drugs Expected to Receive F…
The U.S. Food and Drug Administration (FDA) did not approve any new ADCs in 2023 or 2024. However, with ongoing advancements in technology and clinical research, multiple ADC drugs are antici…
sales@huatengusa.com
+86 0731 89916275